Skip to content
DataLookout
Menu

RADNCT06948331

RADA16 for Aquablation Day Case

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below.

  1. Minor Completed without a posted recruiting period Show 4 more changesShow less
    • Primary completion date changed from estimate of Jul 1, 2026 to Sep 17, 2026
    • Enrollment target: estimated 25 to confirmed 24
    • Study completion date changed from estimate of Aug 1, 2026 to Oct 21, 2026
    • Start date changed from estimate of Apr 1, 2026 to May 14, 2026
  2. Notable Primary completion date: Aug 1, 2025 to Jul 1, 2026
    • Start date: May 1, 2025 to Apr 1, 2026
    • Study completion date: Sep 1, 2025 to Aug 1, 2026
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of Patients Discharged the Same Day as Aquablation
Timeframe: Day 1 (Operative Visit)

Secondary (2)

Mean Post-Operation Hematuria Grade
Percentage of Patients who Experience Dysuria during Follow-Up

Arms and interventions

Men Undergoing AquablationExperimental

Following the Aquablation procedure for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), the surgeon will deliver the PuraStat to the prostatic fossa through the cystoscope sheath into the prostate urethra resection bed.

Devices: PuraStat

Sites

1 site in 1 country

  • NYU Langone HealthNew York, New York, United States